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Oral Presentations S175and exposure to TBI 6CRT. These factors may contribute to
a higher risk of early CVD morbidity and mortality suggesting
that screening and management of modifiable CVD risk factors
should be initiated in HCT survivors.
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CT, allogeneiMean p-value‡ Mean p-value‡ Mean p-value‡ MeanHeight (cm)* 162.1 <.001 159.8 <.001 161.3 <.001 169.8Weight (kg)* 62.0 0.002 59.7 0.002 59.9 <.001 69.9BMI (kg/m^2)* 23.2 0.31 23.4 0.400 22.7 0.064 24.0Waist Circumference
(cm)*78.8 0.646 79.4 0.584 77.2 0.185 79.6PFM, DXA* 33.6 <.001 33.8 0.012 32.3 0.007 28.6Lean Body Mass(kg)* 37.6 <.001 35.0 <.001 35.8 <.001 46.9Systolic BP (mmHg)† 112.2 0.245 116.4 0.509 113.6 0.121 114.3Diastolic BP (mmHg)† 64.9 0.919 65.5 0.615 65.2 0.785 64.8Total Cholesterol
(mg/dL)†170.7 <.001 192 <.001 167.2 0.009 150.6LDL-Cholesterol
(mg/dL)†97.6 0.045 107.7 0.008 93.3 0.16 88.1HDL-Cholesterol
(mg/dL)†43.4 0.295 38.8 0.006 45.2 0.797 45.2Triglycerides (mg/dL)† 154.4 <.001 252.1 0.002 146.9 0.008 82.9Glucose (mg/dL)† 85.2 0.573 90.2 0.04 83.9 0.998 84.4Insulin (mU/L)† 14 0.005 19.2 0.002 12 0.092 9.8Mlbm
(mg/LBM(kg)/min)†,**9.8 0.043 7.2 0.003 10.6 0.359 11.5*adjusted for age-at-study, sex, race, and Tanner.
†adjusted for age-at-study, sex, race, and Tanner, and PFM.
‡P-values for comparison to Controls.
**low Mlbm represents IR.62
RISK FACTORS FOR LATE CARDIOVASCULAR MORBIDITY AND
MORTALITY AFTER HEMATOPOIETIC CELL TRANSPLANTATION
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Martin, P.J.1,2, Mueller, B.A.1,2, Baker, K.S.1,2,3 1Fred Hutchinson Can-
cer Research Center, Seattle, WA; 2University of Washington, Seattle,
WA; 3Seattle Children’s Hospital, Seattle, WA; 4Vanderbilt University,
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Purpose: To examine the effect of pre-transplant treatment and
transplant related-risk factors for late cardiovascular (CV) disease
following hematopoietic cell transplantation (HCT).
Methods: Nested case-cohort study. All 2 yr HCT survivors who
were Washington State residents treated at the Fred Hutchinson
Cancer Research Center from 1985-2006 (n 5 1491; 56% alloge-
neic, 44% autologous) were linked to the state’s hospital discharge
and death registries beginning 2 yrs after HCT (1987-2008). Deathses Associate
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c/autologous dand hospitalizations due to selected CV diagnoses (ischemic heart
disease, cardiomyopathy, dysrhythmia, stroke and other vascular dis-
ease) and related conditions (hypertension, dyslipidemia, diabetes,
renal disease/dialysis) were identified. Relationships (hazard ratios,
HR) among treatment risk factors and CV outcomes were examined
between affected survivors (cases, n 5 436) and a randomly selected
subset of the remaining HCT cohort (n 5 371).
Results: Among these 807 survivors, median age at HCT was 41 (0-
73) yrs and time to event was 5 (2-24) yrs. Individual CV events in-
cluded: 39 CV-related deaths, 56 ischemic heart disease, 80 cardiomy-
opathy, 109 dysrhythmia, 33 stroke, and 52 other vascular disease. In
multivariable models, survivors with cumulative anthracycline expo-
sures $ 300 mg/m2 were more likely to experience CV death (HR
2.8, 95% CI 1.0-7.6), cardiomyopathy (HR 2.1, 95% CI 1.0-4.4),
and dysrhythmia (HR 1.9, 95% CI 1.1-3.3). The association between
anthracycline dose and CV outcomes appeared greater following allo-
geneic than autologous HCT. Allogeneic HCT also was associated
with increased risk of hypertension (HR1.6, 95%CI1.1-2.3), with un-
related donorHCTand chronic graft versus host disease (GVHD) be-
ing significant risk factors. Total body irradiation and chest radiation
were not independently associated with anyCVoutcome. In sub-anal-
yses, survivors with dyslipidemia 1 yr after HCT had an increased risk
of subsequent ischemic heart disease (HR 8.9, 95% CI 3.1-25.9), and
those with both dyslipidemia and hypertension 1 yr after HCT also
had increased risk of subsequent diabetes (HR 4.3, 95% CI 1.6-11.2).
Conclusions: Increased exposure to pre-HCT anthracyclines was
associated with multiple adverse CV outcomes after HCT, including
CV death. HCTwith unrelated donors and chronic GVHDwere as-
sociated with increased risk of hypertension, but otherHCT-specific
exposures were not consistently associated with additional risk of CV
morbidity.63
EVALUATION OF SCALES CORRELATED WITH CLINICIAN AND PATIENT-
PERCEIVED SYMPTOM CHANGE IN OCULAR GRAFT-VERSUS-HOST DIS-
EASE: RESULTS FROM THE CHRONIC GVHD CONSORTIUM
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Measurement scales used to rate the symptomchange in ocular graft-
versus-host disease (GVHD) have not been validated for use in clinical
trials.
Methods: We compared clinician and patient perceptions of eye
symptom changes based on serial clinician or patient-reportedd with Treatment Exposures, Hazard Ratios (95% CI)
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onor, TBI dose, and subsequent relapse/2nd HCT.
